What is King Pharmaceuticals's restricted cash?

King Pharmaceuticals (KG) reported restricted cash of $47.16M in Q1 2026.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

King Pharmaceuticals KG Restricted Cash

Restricted Cash at other companies

SiriusPointSPNT

$153.8M-16.8%

Skyward Specialty Insurance Group, Inc.SKWD

$60.52M+49.1%

Selective Insurance GroupSIGI

$10.72M-90.1%

Universal Insurance HoldingsUVE

$2.64M0.0%

Greenlight Capital RE, Ltd.GLRE

$535.15M-10.1%

Arch Capital GroupACGL

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalents.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's restricted cash?: King Pharmaceuticals (KG) reported restricted cash of $47.16M in Q1 2026.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.